Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
None (2) ·
5-MeO-DMT is a potent 5-HT1A agonist (greater than 5-HT2A). Distinct from N,N-DMT in producing a more unitive, less visual, often ego-dissolving experience. (1) ·
Active alkaloid is cytisine, a nicotinic acetylcholine receptor agonist. NOT a classical 5-HT2A psychedelic. (1) ·
Contains the β-carboline alkaloids harmine, harmaline, and tetrahydroharmine, reversible monoamine oxidase inhibitors (RIMAs) that allow oral DMT to reach the brain. (1) ·
Contains varying amounts of DMT, 5-MeO-DMT, bufotenine, and gramine depending on strain and growing conditions. (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator (15) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist (2) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Root bark contains ~1% N,N-dimethyltryptamine (DMT) and related tryptamines. Oral activity requires MAOI co-administration. (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
None (47) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-00000006-QINU`"' (3) ·
'"`UNIQ--vote-00000008-QINU`"', '"`UNIQ--vote-00000009-QINU`"' (2)
starting dose:
preparations:
None (47) ·
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) ·
Acid/base extraction of fresh young grass for tryptamines; combined with an MAOI (1) ·
Bark/woody stem decocted with a DMT-source plant (''Psychotria viridis'', ''Diplopterys cabrerana'') to make ayahuasca (1) ·
Bright red seeds, traditionally ingested or smoked. Highly toxic, narrow margin between active and lethal (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) ·
Parotid-gland venom expressed onto a glass plate, dried into a shellac-like resin, vaporized and inhaled (1) ·
Root bark acid/base-extracted for DMT; or as the resurrected ''jurema preta'' brew (decocted with an MAOI such as ''Peganum harmala'') (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 54 results in range #1 to #54.